Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have been assigned an average rating of “Hold” from the eleven ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $63.60.
A number of analysts recently weighed in on PTLA shares. Oppenheimer set a $80.00 price target on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 15th. BidaskClub upgraded shares of Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. ValuEngine lowered shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Goldman Sachs initiated coverage on shares of Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a “buy” rating and a $75.00 price target on the stock. Finally, Morgan Stanley lowered their price objective on shares of Portola Pharmaceuticals from $74.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, February 22nd.
PTLA stock traded down $1.28 during trading hours on Friday, reaching $34.83. 1,612,824 shares of the company traded hands, compared to its average volume of 1,811,482. Portola Pharmaceuticals has a 52-week low of $30.10 and a 52-week high of $67.10. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.94 and a quick ratio of 5.92. The firm has a market capitalization of $2,277.60, a price-to-earnings ratio of -7.29 and a beta of 1.34.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.46) by $0.05. The firm had revenue of $9.80 million during the quarter, compared to analyst estimates of $3.71 million. Portola Pharmaceuticals had a negative net margin of 1,268.34% and a negative return on equity of 108.43%. The company’s quarterly revenue was down 28.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.95) earnings per share. equities research analysts expect that Portola Pharmaceuticals will post -4.74 earnings per share for the current fiscal year.
In other news, EVP Tao Fu sold 1,135 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $38.47, for a total transaction of $43,663.45. Following the transaction, the executive vice president now directly owns 18,346 shares in the company, valued at approximately $705,770.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is owned by insiders.
Several hedge funds have recently made changes to their positions in the stock. Oppenheimer Asset Management Inc. boosted its holdings in Portola Pharmaceuticals by 251.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 2,047 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Portola Pharmaceuticals by 54.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 1,141 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Portola Pharmaceuticals during the 3rd quarter worth approximately $178,000. Penbrook Management LLC bought a new stake in shares of Portola Pharmaceuticals during the 4th quarter worth approximately $209,000. Finally, Sei Investments Co. bought a new stake in shares of Portola Pharmaceuticals during the 3rd quarter worth approximately $217,000. 88.43% of the stock is owned by institutional investors and hedge funds.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.